[go: up one dir, main page]

WO2019049144A1 - Compositions pour l'inhibition de la méthyltransférase setd6 - Google Patents

Compositions pour l'inhibition de la méthyltransférase setd6 Download PDF

Info

Publication number
WO2019049144A1
WO2019049144A1 PCT/IL2018/051003 IL2018051003W WO2019049144A1 WO 2019049144 A1 WO2019049144 A1 WO 2019049144A1 IL 2018051003 W IL2018051003 W IL 2018051003W WO 2019049144 A1 WO2019049144 A1 WO 2019049144A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
rela
isolated
cancer
setd6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2018/051003
Other languages
English (en)
Inventor
Dan Levy
Michal FELDMAN-ELMALAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute for Biotechnology in the Negev Ltd
Original Assignee
National Institute for Biotechnology in the Negev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute for Biotechnology in the Negev Ltd filed Critical National Institute for Biotechnology in the Negev Ltd
Publication of WO2019049144A1 publication Critical patent/WO2019049144A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Definitions

  • This disclosure relates to synthetic polypeptide inhibitors of the SET-domain- containing protein 6 (SETD6) methyltransferase, and polypeptide chimeras thereof including at least one cell penetrating peptide.
  • Pharmaceutical compositions and uses thereof for treatment of diseases and conditions associated with overexpression of SETD6 are also described.
  • Epigenetic regulation in concert with genetic alterations, plays a critical role in the pathologies of various human diseases, including the development of cancers.
  • One of the key mechanisms for modulating epigenetic programs involves the addition and removal of methyl groups from lysine residues of histone as well as many non-histone substrates.
  • a lysine residue in a given protein can accept up to three methyl groups, thereby forming mono-, di-, and tri-methylated derivatives (mel, me2 and me3).
  • Methylation of lysine residues in target proteins is performed by protein lysine (K) methyltransferases (PKMTs).
  • K protein lysine
  • PKMTs protein lysine methyltransferases
  • the large number of PKMTs also implies that there is a high degree of substrate specificity, as well as a need for specificity in inhibitory agents.
  • the development of highly specific and potent inhibitors that modulate the enzymatic activity and substrate specificity of the different PKMTs is a major challenge for the pharmaceutical industry.
  • the present disclosure relates to the development of inhibitors of SETD6, a PKMT which was previously determined to be a key regulator of proliferation and inflammatory processes.
  • a RelA-derived peptide and mutants thereof have a cytotoxic effect. Accordingly, described herein is a RelA-derived peptide having an amino acid sequence at least 70% identical to SEQ ID NO: 1, or a fragment, derivative or analog thereof.
  • the described polypeptides are fused at the N- or C- terminal end to at least one cell penetrating peptide.
  • Pharmaceutical compositions including the described polypeptides, and polypeptide-encoding nucleic acids are also described.
  • SETD6 SET -domain-containing protein 6
  • Figure 1 shows a viability assay using peptides at 8uM in HeLa cells.
  • HeLa cells were plated at 25,000 cells/well, supplemented with indicated concentrations of the relevant peptide in serum free medium for 4h, after which cells were washed and fresh complete medium was added overnight. PrestoBlue was added for 20 min after which absorbance at 560/590nm was measured.
  • RelAneg represents a sequence of the RelA protein that is not predicted to be methylated by SETD6. Results are shown for peptides presented in two orientations of the Rl l-NLS CPP and the RelA sequence. Peptides RelAKA-NLS-Rl 1 and RelAKM-NLS-Rl l were tested here only in one orientation. Results were normalized to the control cells, treated the same but with no peptide. Standard error represent triplicates.
  • Figure 2 shows a dose dependent viability assay of peptides in increasing concentrations in HeLa cells.
  • HeLa cells were plated at 25,000 cells/well, supplemented with indicated concentrations of the relevant peptide in serum free medium for 4h, after which cells were washed and fresh complete medium was added overnight. PrestoBlue was added for 20 min after which absorbance at 560/590nm was measured.
  • Peptides presented are all in one orientation, with the RelA sequence at the N-terminal of the peptide. Besides the 4 peptides presented in this Figure, the RelAKM-Rl l mutant was also tested and was found to be non-effective. Results were normalized to the control cells, treated the same but with no peptide. Standard error represent triplicates.
  • Figure 3 shows peptide effects on MDA-MB-231 cells.
  • Cells grown overnight in a 48-wells plate were incubated with the different peptides at a final concentration of 6 uM for 24 hours, before performing a PrestoBlue viability assay.
  • Figure 4 shows peptide effects on U87 cells. Mortality was observed in all cells tested for RelA-NLS-Rl 1 and RelAKA-NLS-Rl 1. Cells grown overnight in a 48-wells plate were incubated with 4.3 ⁇ RelAKA-NLS-Rl 1 and 4.7 ⁇ for the other 3 peptides for 24 hours, before performing a PrestoBlue viability assay.
  • Figure 5 shows that RelA NLS Rl 1 has a toxic effect on B 16 cells, while RelAKR does not have any effect. Living cell percent as shown is calculated from comparison to untreated wells per peptide concentration. After 24 hours of incubation PrestoBlue dyeing was performed. All raw fluorescence data had the average blank (not shown) subtracted.
  • Figure 6 shows that RelA NLS Rl 1 has a higher toxic effect on HepG2 cells than NLS Rl 1 RelAKR, while both have a toxic effect. Shown is living cell percent (compared to untreated wells) per peptide concentration. After 24 hours of incubation (full method described herein) PrestoBlue dyeing was performed. All raw fluorescence data had the average blank (not shown here) subtracted.
  • Figures 7A-7C show the effects of VP22 RelA peptide on wound healing migration assay in HeLa cells.
  • Fig. 7A shows the VP22 (SEQ ID NO: 17) or the VP22-RelA (SEQ ID NO: 16) peptides that were used in the shown experiments.
  • Fig. 7B Cells were plated at 25,000 cells/well, supplemented with 40uM of the VP22 or VP22-RelA peptides in serum free medium for 4h, after which cells were washed and fresh complete medium was added overnight. A scratch was performed across the center of the well, and pictures were taken. 24 h after which pictures were taken again.
  • Fig 7C Migration distance was quantified using ImageJ and results were normalized to cells treated with the negative control peptide VP22. Standard error represent six repeats of each condition.
  • Figures 8A-8B show a dose-dependent viability assay of peptides in increasing concentrations in HeLa cells (Fig. 8A) and MDA-MB-231 cells (Fig. 8B).
  • Cells were plated at 20,000 cells/well, supplemented with indicated concentrations of the VP22 or VP22-RelA peptides in serum free medium for 4h, after which cells were washed and fresh complete medium was added overnight. PrestoBlue was added for 20 min after which absorbance at 560/590nm was measured. Control cells were treated the same but with no peptide. Standard error represent triplicates.
  • Figure 12 shows that the 20 mg/kg treatment groups for RelA and RelAKA peptides resulted in lower median and average values than saline-treated and 5mg/kg RelAKA-treated groups; Dot plot representing all tumor volumes received herein. The X symbol marks the average tumor volume and the square box represents the median. A high variance was apparent in all groups, but mostly in the saline and 5mg/kg RelAKA groups.
  • Figure 13 shows that the 20 mg/kg RelAKA NLS Rl 1 treatment groups' tumors were 40% lighter than the saline treatment group; tumor weights were recorded for each of the different treatment groups.
  • Figure 14 shows that the 20 mg/kg RelAKA NLS Rl 1 group demonstrated weight gain similar to untreated and naive mice; body weight gain was calculated as percent of initial weight. Mice that were not injected with MDA cells were used as a reference and were named the naive group.
  • nucleic and/or amino acid sequences provided herewith are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
  • the Sequence Listing is submitted as an ASCII text file named 3145_3_2_Seqlist_ST25, created September 5, 2018, about 12.3 KB, which is incorporated by reference herein. In the accompanying Sequence Listing:
  • SEQ ID NO: 1 is the combined RelA peptide.
  • SEQ ID NO: 2 is the RelA K310 peptide fragment (RelA).
  • SEQ ID NO: 3 is the RelA K310A peptide fragment.
  • SEQ ID NO: 4 is the RelA K310R peptide fragment.
  • SEQ ID NO: 5 is the RelA K310M peptide fragment.
  • SEQ ID NO: 6 is the NLS cell penetrating peptide.
  • SEQ ID NO: 7 is the Rl l cell penetrating peptide.
  • SEQ ID NO: 8 is the NLS-R11 cell penetrating peptide chimera.
  • SEQ ID NO: 9 is the Rl l-NLS cell penetrating peptide chimera.
  • SEQ ID NO: 10 is the combined RelA-Rl l C-terminal chimera.
  • SEQ ID NO: 11 is the combined Rl 1-RelA N-terminal chimera.
  • SEQ ID NO: 12 is the combined Rl 1-NLS RelA-N-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 13 is the combined RelA-NLS-Rl 1-C-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 14 is the RelA-K310-Rll C-terminal chimera.
  • SEQ ID NO: 15 is the RelA-K310A-Rl l C-terminal chimera.
  • SEQ ID NO: 16 is the RelA-K310R-Rl 1 C-terminal chimera.
  • SEQ ID NO: 17 is the RelA-K310M-Rl l C-terminal chimera.
  • SEQ ID NO: 18 is the Rl l-RelA-K310 N-terminal chimera.
  • SEQ ID NO: 19 is the Rl l-RelA-K310A N-terminal chimera.
  • SEQ ID NO: 20 is the Rl l-RelA-K310R N-terminal chimera.
  • SEQ ID NO: 21 is the Rl l-RelA-K310M N-terminal chimera.
  • SEQ ID NO: 22 is the Rl 1-NLS RelA-K310 N-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 23 is the Rl 1-NLS RelA-K310A N-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 24 is the Rl 1-NLS RelA-K310R N-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 25 is the Rl 1-NLS RelA-K310M N-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 26 is the RelA-K310 NLS Rl l C-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 27 is the RelA-K310A NLS Rl 1 C-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 28 is the RelA-K310R NLS Rl 1 C-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 29 is the RelA-K310M NLS Rl 1 C-terminal cell penetrating peptide chimera.
  • SEQ ID NO: 30 is the Rl l-negative control for the N-terminal fusion with Rl l.
  • SEQ ID NO: 31 is the negative control for an N-terminal chimera of Rl 1-NLS.
  • SEQ ID NO: 32 is the negative control for a C-terminal chimera of Rl 1-NLS.
  • SEQ ID NO: 33 is the RelA-noK310-Rl 1 C-terminal fusion.
  • SEQ ID NO: 34 is the VP22-RelA peptide.
  • SEQ ID NO: 35 is the VP22 peptide.
  • SEQ ID NO: 36 is the NLS- Rl l-RelA-K310R N-terminal cell penetrating peptide chimera.
  • composition, method, or process that includes only those listed features as the active or essential elements, but can include non-active elements in addition.
  • "About" before a numerical value includes minor variations, within 5% of the listed value.
  • the abbreviation, "e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” In case of conflict, the present specification, including explanations of terms, will control.
  • all the materials, methods, and examples are illustrative and not intended to be limiting.
  • Administration The introduction of a composition into a subject by a chosen route.
  • Administration of an active compound or composition can be by any route known to one of skill in the art.
  • Administration can be local or systemic.
  • local administration include, but are not limited to, topical administration, subcutaneous administration, intramuscular administration, intrathecal administration, intrapericardial administration, intra-ocular administration, or topical ophthalmic administration
  • local administration includes routes of administration typically used for systemic administration, for example by directing intravascular administration to the arterial supply for a particular organ.
  • local administration includes intra-arterial administration and intravenous administration when such administration is targeted to the vasculature supplying a particular organ.
  • Local administration also includes the
  • Systemic administration includes any route of administration designed to distribute an active compound or composition widely throughout the body via the circulatory system.
  • systemic administration includes, but is not limited to intra- arterial and intravenous administration.
  • Systemic administration also includes, but is not limited to, topical administration, subcutaneous administration, intramuscular administration, or administration by inhalation, when such administration is directed at absorption and distribution throughout the body by the circulatory system.
  • Antagonist A molecule or compound that tends to nullify the action of another, or in some instances that blocks the ability of a given chemical to bind to its receptor or other interacting molecule, preventing a biological response.
  • Antagonists are not limited to a specific type of compound, and may include in various embodiments peptides, antibodies and fragments thereof, and other organic or inorganic compounds (for example,
  • inhibitor is synonymous with “antagonist”.
  • Apoptosis The process by which cells are programmed to die or lose viability.
  • Neoplasia is a neoplasm (a tumor or cancer), which is an abnormal growth of tissue that results from excessive cell division.
  • a tumor that does not metastasize is referred to as "benign.”
  • a tumor that invades the surrounding tissue and/or can metastasize is referred to as "malignant.”
  • Neoplasia is one example of a proliferative disorder.
  • a “cancer cell” is a cell that is neoplastic, for example a cell or cell line isolated from a tumor.
  • hematological tumors include leukemias, including acute leukemias (such as acute lymphocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia and myeloblastic, promyelocytic, myelomonocytic, monocytic and
  • erythroleukemia chronic leukemias (such as chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin' s lymphoma (indolent and high grade forms), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease,
  • chronic leukemias such as chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia
  • polycythemia vera lymphoma
  • Hodgkin's disease non-Hodgkin' s lymphoma (indolent and high grade forms)
  • multiple myeloma Waldenstrom's macroglobulinemia, heavy chain disease
  • myelodysplastic syndrome hairy cell leukemia and myelodysplasia.
  • solid tumors such as sarcomas and carcinomas
  • solid tumors include fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, and other sarcomas, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lung cancers (such as small cell lung carcinoma and non-small cell lung carcinoma), ovarian cancer, prostate cancer, hepatocellular carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytomas sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas
  • hemangioblastoma hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, neuroblastoma and retinoblastoma).
  • CPP Cell Penetrating Peptide
  • CPPs are synonymous with and encompasses the peptides and sequences known in the art as “protein transduction domain (PTD),” “Trojan Protein,” and “membrane translocating sequence (MTS).”
  • PTD protein transduction domain
  • MTS membrane translocating sequence
  • Typical CPPs are positively charged, with amino acids such as arginine and lysine predominating in their sequence.
  • CPPs include polylysine or polyarginine peptides, for example between 4 and 17 amino acids, penetratin, TAT, SynB l, SynB3, PTD-4, PTD-5, FHV-Coat (35-49), BMV Gag (7-25), HTLV-II Rex (4- 16), D-Tat, R9-Tat, Transportan, MAP, SBP, NLS, FBP, MPG, Rl l, VP22, antp, Pep-1, and Pep-2.
  • polylysine or polyarginine peptides for example between 4 and 17 amino acids, penetratin, TAT, SynB l, SynB3, PTD-4, PTD-5, FHV-Coat (35-49), BMV Gag (7-25), HTLV-II Rex (4- 16), D-Tat, R9-Tat, Transportan, MAP, SBP, NLS, FBP, MPG, Rl l, VP22, antp, Pep
  • Chemotherapeutic agent Any chemical agent with therapeutic usefulness in the treatment of diseases characterized by abnormal cell growth. Such diseases include tumors, neoplasms, and cancer as well as diseases characterized by hyperplastic growth such as psoriasis.
  • a chemotherapeutic agent is an agent of use in treating a breast cancer, an ovarian cancer, or another tumor, such as an anti-neoplastic agent.
  • a chemotherapeutic agent is a radioactive compound.
  • chemotherapeutic agent of use see for example, Slapak and Kufe, Principles of Cancer Therapy).
  • Non-limiting examples of chemotherapeutic agents include cisplatin, paclitaxel, docetaxel, doxorubicin, epirubicin, topotecan, irinotecan, gemcitabine, iazofurine, gemcitabine, etoposide, vinorelbine, tamoxifen, valspodar, cyclophosphamide, methotrexate, fluorouracil, mitoxantrone and vinorelbine.
  • Combination chemotherapy is the administration of more than one agent to treat cancer, including a combination of the peptides described herein and one or more chemotherapeutic agent.
  • Chimera A nucleic acid sequence, amino acid sequence, or protein that comprises nucleic acid sequence, amino acid sequence, or protein from two or more sources, for example amino acid sequence from two or more different species or two or more polypeptides from the same species.
  • chimeric sequences are the result of genetic engineering.
  • the RelA-derived peptides fused to at least one CPP described herein are an example of a polypeptide chimera.
  • Contacting Placement in direct physical association. Includes both in solid and liquid form. Contacting can occur in vitro with isolated cells or in vivo by administering to a subject.
  • Effective amount of a composition A quantity of a composition, including the isolated peptides described herein, sufficient to achieve a desired effect in a subject being treated.
  • An effective amount of a composition can be administered in a single dose, or in several doses, for example daily, during a course of treatment. However, the effective amount of the composition will be dependent on the composition applied, the subject being treated, the severity and type of the affliction, and the manner of administration of the composition.
  • a polynucleotide is said to "encode” a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the mRNA for and/or the polypeptide or a fragment thereof.
  • Expression Control Sequences Nucleic acid sequences that regulate the expression of a heterologous nucleic acid sequence to which it is operatively linked, for example the expression of the described RelA or RelA chimeric polypeptides can be operably linked to expression control sequences.
  • Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence.
  • expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (ATG) in front of a protein-encoding gene, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA and stop codons.
  • control sequences is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
  • Expression control sequences can include a promoter.
  • Functional fragments and variants of a polypeptide include those fragments and variants of the described RelA polypeptides and RelA-CPP chimeras that maintain one or more functions of the parent polypeptides. It is recognized that the gene or cDNA encoding a polypeptide can be considerably mutated without materially altering one or more the polypeptide' s functions. First, the genetic code is well-known to be degenerate, and thus different codons encode the same amino acids. Second, even where an amino acid substitution is introduced, the mutation can be conservative and have no material impact on the essential functions of a protein. Third, part of a polypeptide chain can be deleted without impairing or eliminating all of its functions.
  • insertions or additions can be made in the polypeptide chain; for example adding epitope tags, without impairing or eliminating its functions.
  • Other modifications that can be made without materially impairing one or more functions of a polypeptide include, for example, in vivo or in vitro chemical and biochemical modifications or the incorporation of unusual amino acids. Such modifications include, for example, methylation, acetylation, carboxylation, phosphorylation, glycosylation, ubiquination, labeling, e.g., with radionucleides, and various enzymatic modifications, as will be readily appreciated by those well skilled in the art.
  • radioactive isotopes such as 32 P
  • ligands which bind to or are bound by labeled specific binding partners (e.g. , antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands.
  • Functional fragments and variants can be of varying length.
  • Heterologous A type of sequence that is not normally (i.e. in the wild-type sequence) found adjacent to a second sequence.
  • the sequence is from a different genetic source, such as a virus or organism, than the second sequence.
  • Chimeric polypeptides, such as those described herein are often composed of heterologous sequences.
  • Hyperproliferative disease A disease or disorder characterized by the uncontrolled proliferation of cells. Hyperproliferative diseases include, but are not limited to malignant and non-malignant tumors and psoriasis.
  • a pharmaceutically acceptable fluid composition comprising at least one active ingredient, for example, a protein, peptide, or antibody.
  • the active ingredient is usually dissolved or suspended in a physiologically acceptable carrier, and the composition can additionally comprise minor amounts of one or more non-toxic auxiliary substances, such as emulsifying agents, preservatives, pH buffering agents and the like.
  • non-toxic auxiliary substances such as emulsifying agents, preservatives, pH buffering agents and the like.
  • nucleic acid and proteins that have been isolated include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
  • Linker One or more nucleotides or amino acids that serve as a spacer between two molecules, such as between two nucleic acid molecules or two peptides, for example between a RelA polypeptide as described herein and one or more CPPs, and between CPPs in those polypeptides with multiple CPPs present.
  • Neoplasia malignancy, cancer and tumor: A neoplasm is an abnormal growth of tissue or cells that results from excessive cell division. Neoplastic growth can produce a tumor. The amount of a tumor in an individual is the "tumor burden" which can be measured as the number, volume, or weight of the tumor. A tumor that does not metastasize is referred to as "benign.” A tumor that invades the surrounding tissue and/or can metastasize is referred to as "malignant.” Malignant tumors are also referred to as "cancer.” Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
  • compositions and formulations suitable for pharmaceutical delivery of the compounds herein disclosed are conventional. Remington 's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the compounds herein disclosed. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • Pharmaceutical agent A chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject or a cell.
  • Incubating includes exposing a target to an agent for a sufficient period of time for the agent to interact with a cell.
  • Contacting includes incubating an agent in solid or in liquid form with a cell.
  • Polypeptide A polymer in which the monomers are amino acid residues which are joined together through amide bonds.
  • the term polypeptide or protein as used herein encompasses any amino acid sequence and includes modified sequences such as
  • polypeptide is specifically intended to cover naturally occurring proteins, as well as those that are recombinantly or synthetically produced.
  • polypeptide fragment refers to a portion of a polypeptide which exhibits at least one useful epitope.
  • functional fragments of a polypeptide refers to all fragments of a polypeptide that retain an activity, or a measurable portion of an activity, of the polypeptide from which the fragment is derived
  • Preventing or treating a disease refers to inhibiting the full development of a disease, for example inhibiting the development of myocardial infarction in a person who has coronary artery disease or inhibiting the progression or metastasis of a tumor in a subject with a neoplasm. Treatment refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop.
  • Purified The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified protein preparation is one in which the protein referred to is more pure than the protein in its natural environment within a cell.
  • Radiotherapy The treatment of disease (e.g., cancer or another hyperproliferative disease or condition) by exposure of a subject or their tissue to a radioactive substance.
  • disease e.g., cancer or another hyperproliferative disease or condition
  • Radiotherapy is the medical use of ionizing radiation as part of cancer treatment to control malignant cells. Radiotherapy may be used for curative or adjuvant cancer treatment. It is used as palliative treatment where cure is not possible and the aim is for local disease control or symptomatic relief.
  • Recombinant A nucleic acid that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g. , by genetic engineering techniques.
  • Sequence identity The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Methods of alignment of sequences for comparison are well known in the art, for example the NCBI Basic Local Alignment Search Tool (BLAST), which is available from several sources, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. It can be accessed at the NCBI website, together with a description of how to determine sequence identity using this program.
  • BLAST NCBI Basic Local Alignment Search Tool
  • Subject Living multi-cellular organisms, including vertebrate organisms, a category that includes both human and non-human mammals.
  • Therapeutically effective amount A quantity of compound sufficient to achieve a desired effect in a subject being treated.
  • An effective amount of a compound may be administered in a single dose, or in several doses, for example daily, during a course of treatment. However, the effective amount will be dependent on the compound applied, the subject being treated, the severity and type of the affliction, and the manner of administration of the compound.
  • a therapeutically effective amount of an active ingredient can be measured as the concentration (moles per liter or molar-M) of the active ingredient (such as a small molecule, peptide, protein, or antibody) in blood (in vivo) or a buffer (in vitro) that produces an effect.
  • Vector A nucleic acid molecule as introduced into a host cell, thereby producing a transfected host cell.
  • Recombinant DNA vectors are vectors having recombinant DNA.
  • a vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector can also include one or more selectable marker genes and other genetic elements known in the art.
  • Viral vectors are recombinant DNA vectors having at least some nucleic acid sequences derived from one or more viruses.
  • RelA-derived peptide having an amino acid sequence at least 70% identical to SEQ ID NO: 1, or a fragment, derivative, or analog thereof.
  • the described isolated polypeptides include a polypeptide at least 70% identical to an amino acid sequence set forth as SEQ ID NOs 2-5.
  • the described polypeptides include at least one cell penetrating peptide (CPP) fused to the isolated polypeptide at either the N- or C-terminal ends of the isolated polypeptide.
  • CPP cell penetrating peptide
  • the CPP is fused to the isolated polypeptide through at least one linking amino acid.
  • the described chimeric polypeptides include an amino acid sequence at least 70% identical to SEQ ID NOs: 10-13, or a fragment, derivative or analog thereof, including polypeptides at least 70% identical to an amino acid sequence set forth as SEQ ID NOs 14-29.
  • the described isolated polypeptides and isolated chimeric polypeptides further include an acetyl group at the N- or C-terminal ends.
  • isolated nucleic acids such as an expression vector, including a nucleic acid sequence encoding the described isolated polypeptides or chimeric polypeptides.
  • polypeptides, or isolated nucleic acids are used in therapeutic methods such as in the preparation of a medicament for treatment or prevention of a disease or condition characterized by aberrant overexpression of SET-domain-containing protein 6 (SETD6).
  • diseases or conditions include a SETD6-associated cancer including breast cancer, glioblastoma, cervical cancer, and leukemia.
  • the described compositions can be used in a treatment regimen including an additional chemotherapeutic agent, surgery, or radiotherapy.
  • RelA also known as p65
  • NF- ⁇ nuclear factor kappa-light-chain- enhancer of activated B cells
  • SETD6 NF- ⁇ transcription factor complex family
  • isolated synthetic polypeptides derived from the RelA-SETD6 interacting sequence having an enhanced ability to inhibit SETD6 function.
  • the described synthetic polypeptides include variants and fragments of the following polypeptide including variable position Xi: RKRTYETFXiSIMKKS (SEQ ID NO: 1); wherein in particular embodiments, Xi can be K, A, R, or M.
  • Particular embodiments of the isolated synthetic polypeptides include polypeptides having sequences set forth herein as SEQ ID Nos 2-5.
  • the described synthetic polypeptides are fused to at least one cell penetrating peptide (CPP), which can facilitate passage of the isolated RelA-derived polypeptide from the external environment and into the cellular interior.
  • CPP cell penetrating peptide
  • numerous examples of CPPs exist, and which in fusion with a RelA-derived synthetic polypeptide can be used to produce the chimeric RelA-CPP polypeptides described herein.
  • the RelA-CPP chimeras can include one, two, three, or more CPPs from the same or multiple sources, which can be fused to the RelA-derived polypeptide at the C- and/or N-terminus of the polypeptide.
  • CPPs for use in the described chimeric peptides include the Rl 1 CPP and the NLS CPP.
  • the multiple CPPs can be fused to the RelA peptide in all possible orientations.
  • the orientation (N to C terminal) of peptide segments can be Rl 1, NLS, and RelA; or can be NLS, Rl 1, and RelA. It will be appreciated that similar variations in orientation are possible in embodiments wherein the multiple CPPs are fused to the C terminus of the RelA peptide.
  • RelA-derived peptides that are fused to one or more CPPs are peptides that are set forth herein as SEQ ID Nos 10-29.
  • the RelA-derived pro-proliferative peptide is fused to the VP22 CPP.
  • the at least one CPP is fused directly to the RelA-derived synthetic peptide and/or to other CPPs in the polypeptide chimera.
  • the at least one CPP is fused to the RelA-derived peptide and/or to other CPPs in the polypeptide chimera by way of a peptide linker, which can be one or more amino acids linking the CPP(s) and/or RelA-derived peptide.
  • a peptide linker can be one or more amino acids linking the CPP(s) and/or RelA-derived peptide.
  • Non-limiting examples of linking amino acids or peptides for use in the described polypeptide chimeras include one or more isoleucine and/or tryptophan residues.
  • polypeptides can be produced by any method known to the art.
  • the polypeptides are chemically synthesized.
  • the polypeptides are produced by and purified from a suitable prokaryotic, fungal, plant, or animal cell host into which a suitable polypeptide-expression vector has been introduced.
  • Methods of protein isolation and purification are also standard (e.g. methods of affinity chromatography, size exclusion chromatography and the like).
  • polypeptides include polypeptides that share about 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% sequence identity with the described RelA-derived peptides and chimeras thereof, including the RelA-CPP derived peptides disclosed herein.
  • Other exemplary variants include peptides that differ by only one, two or three amino acids from those set forth herein. In particular embodiments, the variation from those sequences expressly described herein can be conservative substitutions that one of skill will not expect to significantly alter the shape or charge of the polypeptide.
  • the described polypeptides also include those polypeptides that share 100% sequence identity to those indicated, but which differ in post-translational or post- synthesis modifications from the native sequence.
  • the described synthetic polypeptides can be acetylated at the N- or C-terminal ends of the polypeptide.
  • Other examples include conjugation of a palmitic acid group at either terminus of the peptide or other modifications common in the art of polypeptide synthesis (see for examples sigmaaldrich.com/technical- documents/articles/biology/peptide-modifications-n-terminal-internal-and-c-terminal.html).
  • the described RelA-derived peptides and chimeric peptides are provided as a discrete biomolecule.
  • the described polypeptides are a domain of a larger polypeptide, such as an independently-folded structural domain, or an environment-accessible functional domain.
  • nucleic acids encoding the described RelA-derived polypeptides and chimeric polypeptides, including variations due to codon degeneracy and particular nucleic acid sequences optimized for the codon bias of bacterial, animal, and plant cells.
  • the described nucleic acid sequences are contained within a DNA cloning and/or expression plasmid as are standard in the art. It will be appreciated that any standard expression plasmid can be used to express one or more of the described RelA-derived polypeptides and chimeric polypeptide-encoding nucleic acids, as discussed herein. Such plasmids will minimally contain an origin of replication, selection sequence (such as, but not limited to, an antibiotic resistance gene), and expression control sequences operably linked to the RelA-derived polypeptide or chimeric polypeptide-encoding nucleic acid.
  • the expression plasmids include post-translational sequences (e.g. signal sequences to direct polypeptide processing and export) that are encoded in-frame with the RelA-derived polypeptides or chimeric polypeptide-encoding nucleic acids.
  • bacterial expression plasmids include IPTG- inducible plasmids, arabinose-inducible plasmids and the like.
  • Other non-limiting examples of expression induction include light induction, temperature induction, nutrient-induction, and autoinduction, and mammalian- specific DNA expression plasmids.
  • Custom-made expression plasmids are commercially available from suppliers such as New England Biolabs (Ipswich, MA) and DNA 2.0 (Menlo Park, CA).
  • a RelA-derived polypeptide or chimeric polypeptide-expressing plasmid can be designed for specific localized induction in response to a local cellular micro environment, such as the local environment of a particular cancer type.
  • compositions including the described isolated RelA- derived inhibitory polypeptides, chimeric polypeptides, and encoding nucleic acids, for use in treatment or prevention of a disease or condition characterized by overexpression of SET- domain-containing protein 6 (SETD6).
  • SETD6 SET- domain-containing protein 6
  • Exemplary uses include the preparation of a medicament for the described treatment or prevention, as well as methods of treatment by administering the described compositions in a therapeutically effective amount to a subject in need thereof.
  • SETD6 expression is associated with a variety of cancer types, and modulates oncogenesis and cancer progression in a variety of ways.
  • the described compositions can be used in treatment for cancers associated with SETD6 overexpression, including but not limited to breast cancer, melanoma, prostate cancer, cervical cancer, glioblastoma multiforme, colon cancer, ovarian cancer, lung cancer, and leukemia, including chronic lymphoblastic leukemia.
  • the therapeutic compositions described herein can be supplied in any pharmaceutically acceptable composition.
  • one or more RelA-derived polypeptide or chimeric polypeptide-expressing nucleic are provided in a pharmaceutical formulation having a therapeutically effective dose of each therapeutic agent, as described herein, and including standard pharmaceutically acceptable salts, excipients, fillers and the like.
  • Various delivery systems are known and can be used to administer polypeptides and nucleic acids as therapeutic agents.
  • Such systems include, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the therapeutic molecule(s), construction of a therapeutic nucleic acid as part of a retroviral or other vector, and the like.
  • Methods of introduction include, but are not limited to, intrathecal, intradermal, intramuscular, intraperitoneal (ip), intravenous (iv), subcutaneous, intranasal, epidural, and oral routes.
  • the therapeutics can be formulated for administration by any convenient route, including, for example, infusion or bolus injection, topical, absorption through epithelial or mucocutaneous linings (e.g. , oral mucosa, rectal and intestinal mucosa, and the like) ophthalmic, nasal, and transdermal, and may be administered together with other biologically active agents.
  • Pulmonary administration can also be employed (e.g. , by an inhaler or nebulizer), for instance using a formulation containing an aerosolizing agent.
  • therapeutic agents are delivered in a vesicle, in particular liposomes.
  • the described polypeptides and nucleic acids can be formulated for immediate release, whereby they are immediately accessible to the surrounding environment, thereby providing an effective amount of the active agent(s), upon administration to a subject, and until the administered dose is metabolized by the subject.
  • the described polypeptides and nucleic acids can be formulated in a sustained release formulation or system.
  • the therapeutic agents are provided for an extended duration of time, such as 1 , 2, 3, 4 or more days, including 1-72 hours, 24-48 hours,. 16-36 hours, 12-24 hours, and any length of time in between.
  • sustained release formulations are immediately available upon administration, and provide an effective dosage of the therapeutic
  • the sustained release formulation is not immediately available within the subject and only becomes available, providing a therapeutically effective amount of the active compound(s), after the formulation is metabolized or degraded so as to release the active compound(s) into the surrounding environment.
  • a pump may be used.
  • the sustained released formulations include polymeric materials commonly used in the art, such as in implants, gels, capsules, and the like.
  • the described polypeptides and nucleic acids are formulated using methods well known to those with skill in the art.
  • the compounds are formulated with a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia world-wide for use in animals, and, more particularly, in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • Saline solutions, blood plasma medium, aqueous dextrose, and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • the medium may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers such as cyclodextrins, proteins such as serum albumin, hydrophilic agents such as methyl cellulose, detergents, buffers, preservatives and the like.
  • compositions examples include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.
  • the described compositions can, if desired, also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the described compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, all in immediate and sustained-release formulations as understood in the art.
  • the therapeutic can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
  • Therapeutic preparations will contain a therapeutically effective amount of at least one active ingredient, preferably in purified form, together with a suitable amount of carrier so as to provide proper administration to the patient.
  • the formulation should suit the mode of administration.
  • kits comprising the described RelA-derived polypeptide or chimeric polypeptides or encoding nucleic acids are accordingly also contemplated herein.
  • the described RelA-derived polypeptide or chimeric polypeptides or encoding nucleic acid is administered to the subject as a polypeptide.
  • it is administered to the subject by way of an expression vector containing a described nucleic acid.
  • expression of the polypeptide can be constitutive or induced, as is well-known in the art.
  • inducible expression systems can allow for specific targeting of an area, such as a local tumor environment which contains an inducing signal.
  • the described RelA-derived polypeptide or chimeric polypeptide, or encoding nucleic acid thereof is administered to the subject in combination with other pharmaceutical agents for treatment of the disease or condition under treatment.
  • the described polypeptides or nucleic acids can be combined with trastuzumab (Herceptin) therapy.
  • the described compositions can be combined with surgery and/or radiation therapy.
  • the described RelA-derived polypeptide or chimeric polypeptide or encoding nucleic acids can be administered to the subject in sequence (prior to or following) or concurrently with the described compositions.
  • combinations of active ingredients can be administered to a subject in a single or multiple formulations, and by single or multiple routes of administration.
  • the amount of each therapeutic agent for use in the described compositions and methods, and that will be effective, will depend on the nature of the disorder or condition to be treated, as well as the stage of the disorder or condition. Therapeutically effective amounts can be determined by standard clinical techniques. The precise dose to be employed in the therapeutic compositions will also depend on the route of administration for use with the composition, and should be decided according to the judgment of the health care practitioner and each patient' s circumstances.
  • the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors, including the activity of the specific compound, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, and severity of the condition of the host undergoing therapy.
  • the therapeutic compounds and compositions of the present disclosure can be formulated or administered at about the same dose throughout a treatment period, in an escalating dose regimen, or in a loading-dose regime (e.g., in which the loading dose is about two to five times the maintenance dose).
  • the dose is varied during the course of a treatment based on the condition of the subject being treated, the severity of the disease or condition, the apparent response to the therapy, and/or other factors as judged by one of ordinary skill in the art.
  • long-term treatment with the drug is contemplated.
  • Peptides were dissolved to a cone, of lOmM with 5% DMSO (in DDW).
  • Cells were grown in a 75cm2 flask with 12ml DMEM, supplemented, at a final concentration, with 10% FBS, Penicillin (lOOunits/ml) and streptomycin (100 g/ml), in humidified incubator with 5% C02 flow and 37°C.
  • the cells were collected by trypsinization and collected in a 15ml tube at a volume of 12ml. cells were seeded in a 48-well plate at 25,000 cells/well. Cells were Incubated overnight in humidified incubator with 5% C02 flow and 37°C.
  • PrestoBlue cell viability assay was perfumed according to the manufacturer's Instructions.
  • Cytotoxicity of RelA derived-CPP peptide chimeras were tested in vitro with the Presto Blue assay as described. As shown in Figures 1-6, cytotoxicity was tested on cell lines of cervical cancer (HeLa cells, Figures 1 and 2), breast cancer (MDA MB231 cells, Figure 3), gliobastoma (U87 cells, Figure 4), mouse melanoma (B 16 cells, Figure 5), and liver cancer (HepG2 cells, Figure 6).
  • Viability assays revealed that some of the CPPs conferred on the RelA chimeric peptides the ability to induce cell death effect in diverse cancer cell lines, including HeLa cells (Cervical cancer), MDA-MB-231 (Breast cancer), and U87 cells (Glioblastoma brain cancer).
  • This example describes the pro-proliferative activity of the RelA peptide fused to the cell penetrating peptide VP22.
  • VP22-RelA The effect of VP22-RelA on cellular proliferation and migration was determined.
  • Cellular migration was determined through a wound healing assay of HeLa cells treated with the VP22-RelA peptide, or the control peptide VP22. Cells were grown to confluence. The resultant monolayer was then scratched, and treated with VP22-RelA or VP22 control for 24 hours, and imaged at 0 and 24 hours after the scratch was produced. Treatment with the VP22-RelA peptide showed an accelerated rate of cellular migration in comparison to untreated (Fig. 7).
  • VP22-RelA The effect of VP22-RelA on cellular proliferation was measured by PrestoBlue viability assays in HeLa (Cervical cancer) and MDA-MB-231 (Breast cancer) cells.
  • the presented results show a similar trend of proliferation activation by the VP22-RelA peptide as observed in the wound healing assay. This activation was not observed in the control cells, or when the cells were treated with the VP22 negative control peptide (Fig. 8).
  • Example 3 In-vivo evaluation of RelA-CPP chimeric peptide efficacy in reduction of cancer progression and tumor growth
  • This example demonstrates the in vivo effects of RelA chimeric peptides on tumor growth and progression.
  • mice 4T1 breast cancer cells were injected into balb/c mice breast tissue and tumors were allowed to grow with or without addition of RelAKA-NLS-Rl 1.
  • Each balb/C mouse was injected with 2xl0 5 cells into the breast tissue. Tumors were allowed to grow for a period of 4 days without any treatment. At the end of this initial growth period, daily injections of peptides and controls were performed subcutaneously for 10 days at 5 and 20 ⁇ concentrations (until day 15 of the experiment). A total of 18 mice were used (6 per treatment condition). 18 days from the beginning of the experiment (3 days after the last injection) mice were sacrificed and tumor volume and weight; and liver, spleen, and lung weight were determined. The results of this experiment are summarized in Table 2 below, and Figures 9 -10.
  • both RelAKA-NLS-Rl l treated groups gained weight, though the 20mg/kg group gained the least. This was likely due to the effect of the peptide dose on the tumor and its effect on metabolism, or possibly due to the animal size directly.
  • An increase in tumor growth rate was observed in the period between the last injections to the end of the experiment. While the control tumors grew 1.6 times in volume after the last injections, the 5 mg/kg and 20 mg/kg peptide-treated mice had an increase of 1.8 and 2.9 fold respectively, indicating an inhibitory effect of the peptides on tumor growth.
  • Example 4 In vivo effects of RelAKA-NLS-Rll and RelA-NLS-Rll on breast cancer tumors
  • This example demonstrates the effect of the RelA inhibitory chimeras on breast cancer tumors using a mouse model.
  • RelAKA-NLS -R 11 and RelA-NLS-Rl 1 were injected into breast tissue of nude mice, with each mouse receiving 2xl0 5 cells. Tumors were allowed to grow for a period of 3 days. At the end of the growth period, RelAKA-NLS-Rl l and RelA-NLS-Rl l were injected subcutaneously daily for 10 days at 5 and 20 concentrations. At the end of the 10 day injection period, mice were sacrificed. Tumor size and weight; and liver, spleen, and lung weight were measured. Results are shown in Figures 11-14 and in Table 3, below.
  • the relative weights of the spleen, the lungs and the liver remained similar to those of the naive mice, which were not injected with cells, and also similar to those of the saline treatment group- which indicates the peptides had no adverse effect on these vital organs. Like the tumor volume, the tumor weights were also low, allowing a high variance. Despite this, a decrease of nearly 40% was observed in tumor volume for the 20 mg kg RelAKA NLS Rl l treatment.
  • the 20 mg/kg RelAKA NLS Rl l treatment group was shown to gain weight similarly to the naive and the saline-treated groups, but not the 5 mg/kg RelAKA NLS Rl 1 treatment or the 20 mg kg RelA NLS Rl 1 treatment groups.
  • the naive group and the saline groups gained weight in a similar rate, implying that the low weight gain in the 5 mg/kg RelAKA NLS Rl l treatment group and the 20 mg/kg RelA NLS Rl l treatment group is due to the treatment itself.
  • This effect is not shown in the 20 mg/kg RelAKA NLS Rl l treatment group which further shows its lack of toxicity and adverse effects on the mouse body.
  • the 20 mg/kg RelAKA NLS Rl 1 treatment group showed the highest success in this experiment, with a nearly 3.5-fold smaller tumor, weighing 40% less, and showing no adverse effects in either of the tested parameters.
  • Example 5 In vivo effects of RelAKA-NLS-Rll and RelA-NLS-Rll on various well- developed tumors
  • This example demonstrates the effect of the RelA inhibitory chimeras on cancer tumors or various origin, using a mouse model. Tumors are allowed to grow to larger size and be present for a greater length of time prior to treatment than in previous examples.
  • mice at the age of 7 weeks will be anesthetized by an Isoflurane delivery system (SomnoSuite®, Kent scientific). Mice will be injected with 2-15xl0 6 MDA MB231, U87, or U251, B 16, Hela, 4T1 or HepG2 cells in a 60% serum-free DMEM 40% GelTrex (ThermoFisher) (V/V ratios). Mice will be kept on a heating pad until recovery.
  • SomnoSuite® SomnoSuite®, Kent scientific
  • Developing tumors will be measured using a caliper to calculate tumor volume. Upon reaching an average tumor volume of 100mm 3 , 1-100 mg kg, preferably 5-25 mg/kg peptides will be injected subcutaneously on a 5-times-a-week basis for a period of 3 weeks. Mouse weight and tumor volume will be monitored twice each week. Mice will be compared to a negative control group- injected with saline only, and a naive group for organ weight comparison.
  • mice Following the 3 -weeks treatment, mice will be euthanized and tumors will be extracted. Tumor weight will be recorded. The liver, lungs and spleen will also be removed, and weight will be recorded, to observe any toxic effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des inhibiteurs polypeptidiques synthétiques de la méthyltransférase de la protéine 6 contenant le domaine SET (SETD6), et des chimères polypeptidiques de ceux-ci comprenant au moins un peptide de pénétration cellulaire. La présente invention concerne également des compositions pharmaceutiques et leurs utilisations dans le traitement de maladies et d'états pathologiques associés à la surexpression de SETD6.
PCT/IL2018/051003 2017-09-06 2018-09-06 Compositions pour l'inhibition de la méthyltransférase setd6 Ceased WO2019049144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL254361 2017-09-06
IL254361A IL254361A0 (en) 2017-09-06 2017-09-06 Compounds to suppress the methyltransferase setd6

Publications (1)

Publication Number Publication Date
WO2019049144A1 true WO2019049144A1 (fr) 2019-03-14

Family

ID=61837929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2018/051003 Ceased WO2019049144A1 (fr) 2017-09-06 2018-09-06 Compositions pour l'inhibition de la méthyltransférase setd6

Country Status (2)

Country Link
IL (1) IL254361A0 (fr)
WO (1) WO2019049144A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066871A (zh) * 2019-06-04 2019-07-30 中国人民解放军联勤保障部队第九八0医院 高血压性脑出血的早期诊断标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104001A2 (fr) * 2008-02-22 2009-08-27 Ntnu Technology Transfer As Composés oligopeptidiques et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104001A2 (fr) * 2008-02-22 2009-08-27 Ntnu Technology Transfer As Composés oligopeptidiques et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMAMOTO, R. ET AL.: "Critical roles of non-histone protein lysine methylation in human tumorigenesis", NAT REV CANCER, vol. 15, no. 2, 1 February 2015 (2015-02-01), pages 110 - 124, XP055581342 *
PALGRAVE, C. J ET AL.: "Species-Specific Variation in RELA Underlies Differences in NF?B Activity ; A Potential Role in African Swine Fever Pathogenesis", JOURNAL OF VIROLOGY, vol. 85, no. 12, 30 March 2011 (2011-03-30), pages 6008 - 6014, XP055065187, DOI: doi:10.1128/JVI.00331-11 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066871A (zh) * 2019-06-04 2019-07-30 中国人民解放军联勤保障部队第九八0医院 高血压性脑出血的早期诊断标志物

Also Published As

Publication number Publication date
IL254361A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CN103228788B (zh) 抗癌融合蛋白
EP3341394B1 (fr) Protéine recombinée socs3 à perméabilité cellulaire améliorée (icp) et ses utilisations
KR101841211B1 (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
CN103562220A (zh) 抗癌融合蛋白
Huang et al. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery
US11566045B2 (en) Tumor targeting polypeptide and method of use thereof
US8119601B2 (en) Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
US11753453B2 (en) Peptide kinase inhibitors and methods of use thereof
WO2019049144A1 (fr) Compositions pour l'inhibition de la méthyltransférase setd6
US20040110671A1 (en) N-terminal modified recombinant human endostatin and its production
JP2023545546A (ja) 遺伝子発現調節のための非アニオン性ポリヌクレオチド類似体のペプチドに基づく導入
EP4520767A1 (fr) Inhibiteurs de kinases peptidiques et leurs procédés d'utilisation
US20240209045A1 (en) Peptide kinase inhibitors and methods of use thereof
US20240209044A1 (en) Peptide kinase inhibitors and activators and methods of use thereof
CN116615205A (zh) 用于基因表达调节的非阴离子多核苷酸类似物的基于肽的转导
WO2005097994A1 (fr) Muteines se fixant sur la digoxygenine de la proteine de pieris brassicae qui se fixe sur la biline
HK1186209B (en) Anticancer fusion protein
HK1186209A (en) Anticancer fusion protein
IL185500A (en) 1 VDAC preparations and methods for their use for the regulation of apoptosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18854074

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18854074

Country of ref document: EP

Kind code of ref document: A1